VAXCYTE, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- VAXCYTE, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $11.74M, a 444.39% increase year-over-year.
- VAXCYTE, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $2.74M, a 210.41% increase year-over-year.
- VAXCYTE, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $5.02M, a 900.80% increase year-over-year.
- VAXCYTE, INC. stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $2.16M, a 22.71% increase year-over-year.
- VAXCYTE, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $5.61M, a 14.57% increase from fiscal 2022.
- VAXCYTE, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $4.89M, a 62.52% increase from fiscal 2021.
- VAXCYTE, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $3.01M, a 374.33% increase from fiscal 2020.
- VAXCYTE, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $635.00K, a 97.20% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-09-30 | $11.74M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $2.74M 10-Q · filed 2024-11-05 | |
| 2024-03-31 | $5.02M 10-Q · filed 2024-11-05 | |
| 2023-12-31 | $5.61M 10-K · filed 2024-02-27 | |
| 2023-09-30 | $2.16M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $884.00K 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $502.00K 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $4.89M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $1.76M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $324.00K 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $282.00K 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $3.01M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $491.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $466.00K 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $487.00K 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $635.00K 10-K · filed 2023-02-27 | |
| 2020-09-30 | $108.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $297.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $49.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $322.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $314.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $2.00K 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $5.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |